ARIBIO Holdings Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 290690.KQ | 301080.SZ | ABVX | FBRX | ACXP | TCRT | |
|---|---|---|---|---|---|---|
| Market cap | 196.44B | 16.17B | 7.83B | — | 5.64M | 6.19M |
| P/E (TTM) | — | 83.1 | — | — | — | — |
| Forward P/E | — | — | -23.3 | — | -0.6 | -3.0 |
| Price/book | — | 5.9 | 17.4 | — | 0.6 | 6.9 |
| Dividend yield | — | 0.63% | — | — | — | — |
| 1-year change | −17.82% | +57.00% | −13.87% | — | −80.19% | −26.83% |
| Today | +3.18% | +1.77% | +0.88% | 0.00% | +0.98% | −3.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 290690.KQ news ›AriBio strengthens Alzheimer's drug patent shield ahead of pivotal trial readout
With pivotal phase 3 results for its Alzheimer's drug candidate AR1001 just two weeks away, AriBio is tightening its patent protection across major pharmaceutical markets. The Korean biotech company said Tuesday it has secured a Japanese…
AriBio Secures U.S., Japan Patents for Oral Alzheimer's Drug
Patents Cover Use of PDE-5 Inhibitors in Treating Alzheimer's Disease Topline Results Due at U.S. Alzheimer's Clinical Trials Conference in November AriBio is expanding patent protection for its oral Alzheimer's drug candidate ahead of the…
Aribio expands Alzheimer patent portfolio in US, Japan, Europe ahead of Phase 3
Patent wins widen AR1001's reach as Phase 3 readout nears in Boston Aribio said on the 3rd that it completed registration of a Japanese patent for AR1001 (ingredient name: mirodenafil), an oral Alzheimer's disease treatment candidate, and…
AriBio's Oral Alzheimer's Drug AR1001 Registered in Japan, Granted in Europe, Securing Rights in Three Major Markets After US
South Korea's AriBio has completed registration of its Japanese patent for AR1001 (mirodenafil), an oral Alzheimer's disease treatment candidate, and received a notice of intended grant from the European Patent Office. Following last…
AriBio, Fosun, And Alzheimer's Disease: Close, But Perhaps Not Enough
(OTCMKTS:SFOSF) Seeking Alpha - AriBio is nearing phase 3 results for AR1001, a phosphodiesterase-5 inhibitor that limits peroxynitrite-mediated damage in Alzheimer's disease. - Shanghai Fosun Pharmaceuticals (SFOSF) secured regio
AriBio to unveil Phase 3 Alzheimer's drug candidate results on November 16, eyes KRW 1 trillion sales by 2030
“CTAD also regards the presentation of AriBio’s clinical findings as the conference’s most significant event. We have emphasized that, under the embargo, no information should be disclosed prior to the scheduled presentation. We will also…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biz.chosun.com1
- en.sedaily.com1
- finance.biggo.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.